The purpose of the study is to determine whether adding the injection to the steroid taper provides better and longer‑lasting remission than the steroid taper alone. Participants are randomly assigned to receive either the injection or a matching inactive substance, and neither the participants nor the study staff know which one is given. Over 52 weeks, participants continue the steroid at decreasing doses while attending regular check‑ins to monitor symptoms and safety.

The inactive substance used for comparison is a placebo, which looks the same as the active injection but does not contain the medication. Throughout the year, patients are evaluated for sustained remission, any flare‑ups, and overall well‑being using simple questionnaires and routine lab tests. Safety is closely watched for any side effects or unusual laboratory results.

The purpose of the study is to assess the diagnostic accuracy of this imaging approach in patients with suspected disease. Participants receive the injection, undergo the scan shortly afterward, and then have additional scans after about a month and again after six months of standard treatment to see how the uptake of the agent changes over time. The study follows each person for these visits without involving any experimental drugs.

During the trial, participants will be assigned to receive either AP1189 tablets or a placebo. The study will last for a period of 12 weeks, during which the tablets will be taken once a day. This research aims to see if the new medication can help patients manage their condition and potentially reduce the need for steroid treatments.

The study will use different doses of baricitinib (2 mg and 4 mg tablets) or matching placebo tablets. Participants will take the medication orally once daily. The main treatment period will last 24 weeks, during which patients will receive either baricitinib or placebo along with a short course of glucocorticoids. The study will monitor how well the treatment controls disease activity when patients are no longer taking glucocorticoids.

Throughout the study, healthcare providers will regularly check participants’ disease activity using various measurements to determine how well the treatment is working. The trial will evaluate whether patients can achieve good disease control without needing to continue steroid medication after receiving the study treatment.

Two different RSV vaccines will be used in the study: Arexvy and Abrysvo. Both vaccines are given as a single injection into the muscle. The purpose is to determine if the medications used to treat inflammatory rheumatic disease affect how well the body develops protection after receiving the RSV vaccine.

Participants will receive one dose of the RSV vaccine and will have blood samples taken before and after vaccination to measure their body’s immune response. The study will also monitor any side effects that may occur after vaccination. This information will help healthcare providers better understand how these treatments influence vaccine effectiveness in patients with inflammatory rheumatic disease.

Participants in the study will take either baricitinib or a placebo in the form of film-coated tablets. The study will be conducted over several weeks, with participants receiving either 2 mg or 4 mg doses of baricitinib. The treatment period will last up to 44 weeks, during which the participants’ progress will be monitored. The study aims to achieve remission of the disease without the use of glucocorticoids, which are commonly used to manage symptoms but can have side effects when used long-term.

The trial will assess various outcomes, including the proportion of participants who achieve remission without glucocorticoids at different time points, the total amount of glucocorticoids used, and the number of relapses experienced by participants. Additionally, the study will evaluate patient-reported outcomes such as fatigue and pain levels, as well as laboratory markers of inflammation. The safety of baricitinib will also be closely monitored, including any side effects or changes in health indicators. The study is expected to conclude by the end of 2025.

The purpose of the study is to determine if rituximab can help reduce the need for glucocorticoids, which are a type of steroid medication often used to manage inflammation in polymyalgia rheumatica. Participants in the study will receive either rituximab or a placebo and will be monitored over a period of time to assess their response to the treatment. The study will look at various outcomes, such as the number of patients who can stop using glucocorticoids without their symptoms returning, and the overall improvement in their condition.

Throughout the study, participants will have regular check-ups to track their progress and any changes in their symptoms. The study will also evaluate the safety of rituximab by monitoring any side effects that may occur. The goal is to find out if rituximab can be a beneficial treatment option for people with newly diagnosed polymyalgia rheumatica, potentially offering an alternative to long-term steroid use.

The purpose of the study is to investigate whether using leflunomide can help prevent relapses, or the return of symptoms, in patients with polymyalgia rheumatica who are reducing their use of corticosteroids, a type of medication often used to treat this condition. The study will involve taking the medication or placebo orally, meaning by mouth, over a period of time.

Participants will be monitored to see how long it takes for a relapse to occur within a 12-month period. The study aims to provide more information on the effectiveness of leflunomide in managing polymyalgia rheumatica and helping patients maintain their health while tapering off corticosteroids.

The purpose of the study is to determine if the dose of prednisolone needs to be adjusted when it is used together with Clofutriben to achieve the same level of effectiveness. Participants in the study will take either prednisolone with Clofutriben or prednisolone with a placebo. The study will last for a period of up to 28 days, during which participants will take the medications orally in the form of tablets. The trial aims to gather information on how these medications work together and whether any changes in dosage are necessary.

Throughout the study, various health markers will be monitored, such as levels of fibrinogen, a protein involved in blood clotting, and C-reactive protein, which is a marker of inflammation in the body. Additionally, tests like the oral glucose tolerance test will be conducted to assess how the body processes sugar. The study is expected to provide valuable insights into the treatment of PMR and help improve the management of this condition.

The purpose of the study is to determine how effective rituximab is in treating patients with relapsing polymyalgia rheumatica, meaning the disease symptoms return after initially improving. Participants in the study will receive either rituximab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor patients over a period of time to see if they can achieve remission, which means the symptoms of the disease are reduced or disappear, without needing glucocorticoids.

Throughout the study, researchers will observe how many patients can maintain remission without glucocorticoids at different time points, such as after one year and two years. They will also track any relapses, which are times when the disease symptoms return, and any side effects that may occur. The study will help to understand if rituximab can be a beneficial treatment option for people with polymyalgia rheumatica who experience relapses and need to reduce their use of glucocorticoids.